Long term, tamoxifen stops more cancer than Evista
Longer-term results from a head-to-head trial of two drugs that prevent breast cancer shows that tamoxifen works better than rival Eli Lilly and Co’s Evista, but with a greater risk of some other cancers and blood clots.
Read more on Reuters via Yahoo! News
